Cybin Announces Closing of $175 Million Registered Direct Offering
TORONTO — Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative del
(Financial Post, 2025-10-31T20:21:51Z)